Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| University of Cambridge | OTHER |
Not provided
Not provided
Not provided
Not provided
The CamPROBE study investigates the rate of infective complications using the Cambridge Prostate Biopsy Device method of local anaesthetic transperineal prostate biopsies.
The current method for diagnosing prostate cancer requires a biopsy needle to pass through the bowel wall to reach the prostate. Bacteria in the bowel inevitably enter the urinary system and blood stream. A significant number of men develop infections despite preventative antibiotics (1 in 10 develop fevers/shivers and 1-2 in 100 get a life-threatening infection). It is crucial we find a safer biopsy method for suspected prostate cancer as over 1 million rectal biopsies occur each year.
A safer alternative device was developed, performed under local anaesthetic using the transperineal route: CamPROBE (Cambridge Prostate Biopsy Device). CamPROBE biopsies are taken through the perineum (the area under the testicles), so there is no infection risk, and it's just as good at diagnosing prostate cancer. This investigation progresses from a prototype to a disposable, single use device that any UK hospital can use. The study will assess CamPROBE's ability to reduce infections from prostate biopsies and its usability as an alternative to the current standard biopsies.
Men recommended to undergo a prostate biopsy will be eligible for this multi-centre study. For each patient, the study will take approximately 30 days, consisting of: recruitment, 1 day for the procedure (replaces the standard biopsy pathway) and questionnaires on day 1, 7 and 30. This timeframe will not introduce delays in the patients' normal standard care pathway. Patients will have a transperineal biopsy with CamPROBE instead of the current transrectal method. Biopsy samples will be treated the same as standard procedure. Patients' acceptability of the procedure and complications will be measured using patient self-reported questionnaires.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| CamPROBE biopsy method | Experimental | To be completed |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| CamPROBE | Device | To be completed |
|
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of Infection | Changes in incidence of infection as measured using patient self-reported Follow-Up Questionnaires and telephone assessments. | 30 days post biopsy |
| Measure | Description | Time Frame |
|---|---|---|
| Patient reported pain score | Patient reported pain scores as measured using patient self-reported questionnaires. | 30 days post biopsy |
| Biological functions post biopsy | Patient biological functions as measured using patient self-reported questionnaires |
| Measure | Description | Time Frame |
|---|---|---|
| Clinician Perception | Clinician perception of the device and the performance of the CamPROBE assessed using Clinical Performance Assessment questionnaire | 1 day |
Inclusion Criteria:
To be included in the clinical investigation the participant must:
Exclusion Criteria:
The presence of any of the following will preclude participant inclusion:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Cambridge University Hospitals NHS Foundation Trust - Addenbrooke's Hospital | Cambridge | CB2 0QQ | United Kingdom |
| Type | Date | Date Unknown |
|---|---|---|
| Release | Oct 25, 2021 | |
| Reset | Dec 6, 2021 | |
| Release | Jun 29, 2022 | |
| Reset | May 2, 2023 |
Not provided
Not provided
| Release Date | Unrelease Date | Unrelease Date Unknown | Reset Date | MCP Release Number |
|---|---|---|---|---|
| Oct 25, 2021 | Dec 6, 2021 | |||
| Jun 29, 2022 |
| ID | Term |
|---|---|
| D011471 | Prostatic Neoplasms |
| ID | Term |
|---|---|
| D005834 | Genital Neoplasms, Male |
| D014565 | Urogenital Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| 30 days post biopsy |
| Patient willingness to have a repeat biopsy | Patients' willingness to have a repeat biopsy as measured using patient self-reported questionnaires | 30 days post biopsy |
| May 2, 2023 |
| D005832 |
| Genital Diseases, Male |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D011469 | Prostatic Diseases |
| D052801 | Male Urogenital Diseases |